Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer

Summary

This phase II trial is studying fulvestrant to see how well it works in treating patients with recurrent, persistent, or metastatic endometrial cancer. Estrogen can stimulate the growth of cancer cells. Hormone therapy using fulvestrant may fight cancer by blocking the uptake of estrogen by the tumor cells.

Timeline

Start

2004-08-30

Primary completion

2008-03-17

Completion

—

Drugs

Indications